NZ614707B2 - Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto - Google Patents
Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto Download PDFInfo
- Publication number
- NZ614707B2 NZ614707B2 NZ614707A NZ61470712A NZ614707B2 NZ 614707 B2 NZ614707 B2 NZ 614707B2 NZ 614707 A NZ614707 A NZ 614707A NZ 61470712 A NZ61470712 A NZ 61470712A NZ 614707 B2 NZ614707 B2 NZ 614707B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- igg
- iga
- igm
- blood brain
- brain barrier
- Prior art date
Links
- 230000035842 BLOOD BRAIN BARRIER PERMEABILITY Effects 0.000 title claims abstract description 19
- 230000003870 intestinal permeability Effects 0.000 title description 16
- 238000001514 detection method Methods 0.000 title description 10
- 239000000463 material Substances 0.000 title description 7
- 239000000427 antigen Substances 0.000 claims abstract description 122
- 108091007172 antigens Proteins 0.000 claims abstract description 122
- 102000038129 antigens Human genes 0.000 claims abstract description 122
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims abstract description 109
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims abstract description 83
- 239000002158 endotoxin Substances 0.000 claims abstract description 80
- 108090001123 antibodies Proteins 0.000 claims abstract description 51
- 102000004965 antibodies Human genes 0.000 claims abstract description 51
- 230000035699 permeability Effects 0.000 claims abstract description 41
- 230000001580 bacterial Effects 0.000 claims abstract description 33
- 238000005259 measurement Methods 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 230000000968 intestinal Effects 0.000 claims description 56
- 102100009596 HP Human genes 0.000 claims description 50
- 108010027843 zonulin Proteins 0.000 claims description 50
- 102000003940 Occludin Human genes 0.000 claims description 47
- 108090000304 Occludin Proteins 0.000 claims description 47
- 210000004556 Brain Anatomy 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 30
- 210000004369 Blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 230000015556 catabolic process Effects 0.000 claims description 25
- 201000010874 syndrome Diseases 0.000 claims description 23
- 238000003745 diagnosis Methods 0.000 claims description 21
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 18
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 18
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 claims description 15
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 claims description 15
- 210000001578 Tight Junctions Anatomy 0.000 claims description 15
- 230000001537 neural Effects 0.000 claims description 14
- 108010043137 Actomyosin Proteins 0.000 claims description 11
- 210000004692 Intercellular Junctions Anatomy 0.000 claims description 11
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 11
- 108010053256 zonula occludens toxin receptor Proteins 0.000 claims description 11
- 230000003959 neuroinflammation Effects 0.000 claims description 10
- 210000000936 Intestines Anatomy 0.000 claims description 9
- 102000015528 Myelin Basic Protein Human genes 0.000 claims description 8
- 108010025255 Myelin Basic Protein Proteins 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 7
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 102000024070 binding proteins Human genes 0.000 claims description 5
- 108091007650 binding proteins Proteins 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 3
- 206010057840 Major depression Diseases 0.000 claims description 3
- 210000003296 Saliva Anatomy 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010061536 Parkinson's disease Diseases 0.000 claims description 2
- 230000002518 glial Effects 0.000 claims description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 230000003619 fibrillary Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 238000010998 test method Methods 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 50
- 206010009839 Coeliac disease Diseases 0.000 description 19
- 201000006417 multiple sclerosis Diseases 0.000 description 19
- 231100000699 Bacterial toxin Toxicity 0.000 description 18
- 239000000688 bacterial toxin Substances 0.000 description 18
- 210000004027 cells Anatomy 0.000 description 17
- 238000004166 bioassay Methods 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 108010068370 Glutens Proteins 0.000 description 11
- 210000004698 Lymphocytes Anatomy 0.000 description 11
- 230000000890 antigenic Effects 0.000 description 11
- 235000021312 gluten Nutrition 0.000 description 11
- 206010003816 Autoimmune disease Diseases 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 229920002521 Macromolecule Polymers 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000004770 neurodegeneration Effects 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000000987 Immune System Anatomy 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000006171 gluten free diet Nutrition 0.000 description 8
- 235000020884 gluten-free diet Nutrition 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000002889 Endothelial Cells Anatomy 0.000 description 7
- 230000002496 gastric Effects 0.000 description 7
- 230000002757 inflammatory Effects 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 206010003591 Ataxia Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010061711 Gliadin Proteins 0.000 description 6
- 239000012523 bacterial endotoxin Substances 0.000 description 6
- 230000005549 barrier dysfunction Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 101700024603 ANNU Proteins 0.000 description 5
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 5
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 5
- 210000001744 T-Lymphocytes Anatomy 0.000 description 5
- 101700034322 TGAS Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960000511 lactulose Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000000529 probiotic Effects 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 101700012968 tgl Proteins 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 231100000765 Toxin Toxicity 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 150000002605 large molecules Chemical class 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 230000000770 pro-inflamatory Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 108020003112 toxins Proteins 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- 108030007212 EC 3.4.21.79 Proteins 0.000 description 3
- 102100004391 GZMB Human genes 0.000 description 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 description 3
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000003960 inflammatory cascade Effects 0.000 description 3
- 108010027445 interleukin-22 receptor Proteins 0.000 description 3
- 238000009114 investigational therapy Methods 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 102000002029 Claudin Human genes 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 2
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229940078795 Lactoferrin Drugs 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 102100014893 MMP3 Human genes 0.000 description 2
- 101700040359 MMP3 Proteins 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- 210000004248 Oligodendroglia Anatomy 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010075569 Rheumatoid Factor Proteins 0.000 description 2
- 210000001138 Tears Anatomy 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 229940046008 Vitamin D Drugs 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 201000002055 autistic disease Diseases 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RMRCNWBMXRMIRW-WZHZPDAFSA-L cyanocob(III)alamin Chemical compound O[C@@H]1[C@H](OP([O-])(=O)O[C@H](C)CNC(=O)CC[C@@]2([C@H]([C@@H]3[C@]4(C)[N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(=C4[N+]6=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C=C4[N+]7=C([C@H](C4(C)C)CCC(N)=O)C(=C2N3[Co-3]6527C#N)C)C)CC(N)=O)C)[C@@H](CO)O[C@@H]1N1C(C=C(C(C)=C3)C)=C3[N+]2=C1 RMRCNWBMXRMIRW-WZHZPDAFSA-L 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial Effects 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001703 neuroimmune Effects 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 210000001130 Astrocytes Anatomy 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 101700018671 BTG3 Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 102000025380 C-Reactive Protein Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 101700078950 CD44 Proteins 0.000 description 1
- 102100003735 CD44 Human genes 0.000 description 1
- 102100004728 CDH1 Human genes 0.000 description 1
- 101700016900 CDH1 Proteins 0.000 description 1
- 101700034283 CRO Proteins 0.000 description 1
- 102100015724 CRP Human genes 0.000 description 1
- 102000018803 Calgranulin A Human genes 0.000 description 1
- 108010052500 Calgranulin A Proteins 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 206010051288 Central nervous system inflammation Diseases 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- QVFWZNCVPCJQOP-UHFFFAOYSA-N Chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 description 1
- 229940092534 Citrobacter koseri Drugs 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 206010014128 Echopraxia Diseases 0.000 description 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 102100014479 GRIA3 Human genes 0.000 description 1
- 108060003206 GRIA3 Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000588729 Hafnia alvei Species 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229940017800 Lactobacillus casei Drugs 0.000 description 1
- 240000004403 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 102000001777 Matrix Metalloproteinase 8 Human genes 0.000 description 1
- 108010015318 Matrix Metalloproteinase 8 Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010027538 Microcytic anaemia Diseases 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 229940076266 Morganella morganii Drugs 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 206010028323 Muscle pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001191345 Osa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 101710044433 SAG Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 231100000617 Superantigen Toxicity 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100017295 TGM2 Human genes 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010092132 anti-IgM Proteins 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 101710003567 cro-HTT Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002183 duodenal Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 210000004783 epithelial tight junctions Anatomy 0.000 description 1
- 230000003492 excitotoxic Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 201000002146 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 1
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000024799 morphogenesis of a branching structure Effects 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000575 proteomic Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 101710040918 shg Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 108010058974 transglutaminase 2 Proteins 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/709—Toxin induced
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Abstract
Disclosed is a method of testing a sample from a human, comprising: measuring a first signal derived from binding of a first antibody fraction of the sample to a bacterial lipopolysacccharide; and measuring a second signal derived from binding of a second antibody fraction of the sample to one or more human antigen, selected from at least one of (a) one or more gut-related antigen and (b) one or more blood brain barrier-related antigen, wherein the measurement of the first signal is related to the presence of antibody to the bacterial lipopolysaccharide in the human; and the measurement of the second signal is related to, for the one or more gut-related antigen, gut permeability in the human; and the measurement of the second signal is related to, the one or more blood brain barrier related antigen, blood brain barrier permeability in the human. e or more human antigen, selected from at least one of (a) one or more gut-related antigen and (b) one or more blood brain barrier-related antigen, wherein the measurement of the first signal is related to the presence of antibody to the bacterial lipopolysaccharide in the human; and the measurement of the second signal is related to, for the one or more gut-related antigen, gut permeability in the human; and the measurement of the second signal is related to, the one or more blood brain barrier related antigen, blood brain barrier permeability in the human.
Description
PCT/U82012/022796
METHOD FOR DETECTION OF INTESTINAL, AND BLOOD-BRAIN BARRIER
PERMEABILITY AND TESTING MATERIALS THERETO
RELATED APPLICATION
The present application claims the benefit of US. Previsional Application No.
61/437,244 filed January 28, 2011, which is incorporated herein in its entirety by reference.
FIELD OF THE INVENTION
The present invention relates to methods, assays, and kits for aid in detection and
diagnosis of intestinal and blood-brain barrier permeability.
BACKGROUND OF THE INVENTION
Compared to the other cellular organs in the human body, the intestinal epithelial cells
are exposed to an enormous number of antigens that ate from ingested foods, yeast,
ia and viruses. Some of these bacterial antigens pose no threat to the mucosal immune
, while others may be l to the host. The intestinal immune system monitors these
bacterial antigens in the intestinal lumen by allowing a few molecules to permeate the
epithelium, where they interact with the mucosal and systemic immune system, in order to
develop regulatory T-cell function or tolerance for these antigens. However, inappropriate or
excessive re of the intestinal immune system to these bacterial antigens may cause the
own of this regulatory mechanism and lead to gastrointestinal disease (1). Therefore, an
understanding of the physiology of the n uptake is central to an appreciation of the
pathogenesis of disease, including inflammatory and autoimmune reactions (2).
These and all other extrinsic materials discussed herein are incorporated by reference in
their entirety. Where a ion or use of a term in an incorporated reference is inconsistent or
contrary to the definition of that term provided herein, the definition of that term provided herein
applies and the definition of that term in the reference does not apply.
Increased intestinal permeability is thought to be an early stage that precedes the onset of
several autoimmune disorders (3-6). For this reason, there has recently been an sed interest
in the role of intestinal barrier dysfunction in the pathogenesis of many pathological conditions
ing the GI tract as well as extra-intestinal organs ing the nervous system (7). This
dysregulation of the intestinal barrier function as the ical doorway to inflammation,
autoimmunity and cancer was discussed in a review article by Fasano (7). In this review article,
3037416891HA3510078N2PR
as well as an earlier Fasano article (4), Fasano emphasized that the primary functions of the
gastrointestinal tract have traditionally been ved to be limited to the digestion and
absorption of nutrients and to electrolytes and water homeostasis. A more attentive analysis of
the anatomic and fiinctional arrangement of the gastrointestinal tract, however, suggests that
another extremely important function of this organ is its ability to regulate the trafficking of
macromolecules between the environment and the host through a barrier mechanism. Together
with the sociated lymphoid tissue and the neuroendocrine network, the intestinal epithelial
barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and
immunity to non-self antigens.
Zonulin/occludin are physiological modulators of paracellular tight junctions that are
involved in the trafficking of macromolecules and therefore in the balance between immune
response and tolerance (7). When the finely tuned intestinal barrier proteins are dysregulated in
those individuals genetically susceptible to environmental s, the possibility arises for both
intestinal disorders such as celiac disease, Crohn's disease and ulcerative colitis, and extra-
intestinal autoimmune diseases such as arthritis, lupus, thyroiditis, es, and even le
sclerosis (MS), malignancies and major depression (8-14). One of the major nmental
factors that can contribute to the pathophysiology of gut and brain barrier dysfunction, and hence
its involvement in intestinal and extra~intestinal munities, is bacterial lipopolysaccharides
(LPS). Due to gut microbiota dysbiosis and ial translocation, LPS is apparently sible
for the activation of toll—like receptors on lial cells and activation of an inflammatory
cascade which s first in gut barrier and then blood—brain barrier dysfunction (14). The role
of LPS in the induction of "leaky gut" and "leaky brain" syndrome is shown in Figure 1.
Figure l emphasizes that GI tract abnormality can compromise the integrity of the gut
barrier and increases the entry of undigested antigens into circulation, thus challenging the
immune system. Reaction to these antigens activates immune and inflammatory es,
resulting in the production of pro-inflammatory cytokines, an array of antibodies, and increased
intestinal barrier permeability (or "leaky gut" me). If intestinal r dysfunction is left
unmanaged, the result could be neuroinflammation, neuroinvasion and neurodegeneration.
3037416892HA8510078NZPR
Therefore, there is a need for a non-invasive method, apparatus, and assays for the
measurement of intestinal permeability to large antigenic molecules that can challenge the
immune , inducing inflammation, which may result in the opening of blood~brain barriers
first, followed by neuroinflammation and neurodegeneration thereafter (15—25).
OBJECT
It is an object of the present invention to provide a method of testing a sample from a
human, a method of diagnosing a disease, a test plate and/or a method of assisting in diagnosing
a disease or syndrome that overcome or rate at least one of the disadvantages of the prior
art. Any s referred to herein should be read disjunctively and with the alternate object of to
at least provide the public with a useful choice.
SUMMARY OF THE INVENTION
The inventive subject matter of the present invention provides tus, systems, assays
and methods in which a sample from a human being can be tested to assist in ion and
sis of intestinal and/or blood-brain barrier permeability
In certain aspects of the present invention, one or more fractions of a sample is / are
tested for binding (1) to a bacterial toxin, and (2) binding to a native antigen selected from at
least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. In certain
aspects, the bacterial toxin can advantageously se a lipopolysaccharide.
When testing for intestinal permeability, the native gut-related antigen is preferably
selected from the list consisting of: (1) an intestinal structural protein; (2) a tight junction
n; (3) a binding or to the tight junction protein; and (4) a cell on protein. In
examples of certain aSpects of the present invention, testing occurs for antibodies to one or more
of actin/actomyosin, in and/or zonulin, intestinal ZOT receptor, and matrix
metalloproteinase~3 (MMP~3).
When testing for a blood brain barrier permeability, the blood brain barrier-related
antigen is ably selected from the list consisting of: (1) a blood brain barrier protein; (2) a
glial fibrillary acidic protein (GFAP); (3) a matrix metalloproteinase (MMP), ( 4) a brain ZOT
6891HA5510078NZPR
binding protein; (5) a brain ZOT receptor; (6) a calprotectin; and (7) a myelin basic protein. In
examples of certain aspects of the present invention, g occurs for antibodies to one or more
of (1) a blood brain barrier protein; (2) a glial fibrillary acidic protein (GFAP); and (3) a matlix
metalloproteinase (MMP).
From a diagnostic perspective, analysis of test results from one or more of the foregoing
described methods can be used to assist in the detection and/or diagnosis of a disease associated
with leaky gut syndrome and/or ive blood brain barrier permeabiiity.
In n s of the present ion, the detection of the samples binding to the
respective components can be performed with an immunoassay, including, but not limited to
ELISA assay, RIA assay, latex agglutination, beads assay, proteomic assay, and other
immunoassays known to one of ordinary skill in the art.
in certain aspects of the present invention, test plates and kits for conducting the
immunoassay can also be provided, including for example an improved test plate having as
bound peptides: (1) a bacterial toxin; and (2) a native antigen comprising at least one of (a) a gut-
related antigen and (b) a blood native brain barrier-related antigen.
In particularly preferred test plates used to assist in the detection and diagnose or
ise identify a disease associated with leaky gut syndrome, the gut-related antigen can
W0 2012/103324 PCT/U82012/022706
advantageously be selected from the list consisting of: (1) an intestinal structural protein; (2) a
tight junction protein; (3) a binding or to the tight junction protein; and (4) a cell junction
protein.
In particularly preferred test plates used to diagnose or otherwise identify a disease
associated with excessive blood brain barrier permeability, the blood brain barrier-related
antigen can ageously be selected from the list consisting of: (l) a blood brain barrier
protein; (2) a glial fibrillary acidic protein ; (3) a matrix metalloproteinase (MMP), (4) a
brain ZOT g protein; (5) a brain ZOT or; (6) a calprotectin; and (7) a myelin basic
It is contemplated that test kits can include one or more plates that collectively test for
both a first set of antigens ated with leaky gut syndrome and a second set of antigens
associated with excessive blood brain barrier permeability.
From a more general perspective, methods and apparatus are contemplated herein for
assisting in the detection and diagnosis of a e associated with excessive permeability of an
anatomical barrier, comprising: obtaining and analyzing test results from an antibody test panel
that produces signals from binding of a sample from the patient to a bacterial toxin, and a native
antigen selected from at least one of (a) a gut-related antigen and (b) a blood native brain barrier—
related antigen.
In all of these contemplated methods and apparatus, the samples can comprise any
suitable bodily , including for example a whole blood sample, a blood serum/sera sample,
a saliva sample, or a sample from other bodily fluids.
It is still r contemplated that methods and apparatus contemplated herein can be
used to assist in differentially diagnosing diseases related to (l) a gut flora dysbiosis, and (2) a
breakdown in intestinal barrier. For example, as tly contemplated, a diagnosis related to
gut flora dysbiosis would tend to be indicated when the test results include a positive result for
any of IgA, lgM, and IgG to the ial toxin of lipopolysaccharide, and negative results for all
of lgA, IgM, and IgG to in and zonulin, and a negative result for IgG to actomysin.
Differential diagnosis is also contemplated to be aided by distinguishing between a
breakdown in intestinal barrier due to a paracellular y and a ellular pathway.
Regarding breakdown through paracellular pathways, a diagnosis related to breakdown in
intestinal barrier by bacterial antigens would tend to be ted when the test results include a
positive result for any of IgA, IgM, and IgG to the bacterial toxin of lipopolysaccharide, and
positive results for any of lgA, IgM, and IgG to occludin or zonulin, and a negative result for
IgG to actomysin. In contrast, a diagnosis related to breakdown in intestinal barrier other than
W0 20121103324 PCT/U82012/022706
by bacterial antigens would tend to be indicated when the test s include a ve result for
all of IgA, IgM, and IgG to the bacterial toxin of lysaccharide, and positive results for any
ofIgA, IgM, and IgG to occludin or zonulin, and a negative result for IgG to actomysin.
Regarding breakdown through transcellular pathways, a diagnosis related to breakdown
in intestinal barrier by bacterial antigens would tend to be indicated when the test results include
a positive result for any of lgA, IgM, and IgG to the bacterial toxin of lipopolysaccharide, and
ve results for all of IgA, IgM, and IgG to occludin and n, and a positive result for
IgG to actomysin.
Also according to the discoveries discussed herein, a diagnosis related to both breakdown
in intestinal and blood brain barrier ity d by the bacterial toxin would tend to be
indicated where the test results include a positive result for any of IgA, IgM, and IgG to the
bacterial toxin of lipopolysaccharide, and positive results for any of IgA, IgM, and IgG to
occludin and zonulin, a positive result for any of IgA, IgM, and IgG to blood brain barrier
proteins, and a positive result for any of IgA, IgM, and IgG to neuronal antigens.
In contrast, a diagnosis related to both breakdown in inal and blood brain barrier
integrity induced by factors other than the bacterial toxin are likely where the test results include
a negative result for each of IgA, IgM, and IgG to the bacterial toxin of lipopolysaccharide, and
ve results for any of IgA, IgM, and IgG to occludin and zonulin, a positive result for any of
IgA, IgM, and IgG to blood brain barrier ns, and a positive result for any of IgA, IgM, and
IgG to neuronal antigens.
Still further it is plated that gut flora dysbiosis can occur without breakdown in
intestinal barrier integrity, but with breakdown in the blood brain barrier integrity. For example,
a diagnosis related to gut flora dysbiosis in that situation could tend to be indicated where the test
results include a positive result for any of IgA, lgM, and IgG to the bacterial toxin of
lipopolysaccharide, and negative results for each of IgA, IgM, and IgG to occludin and zonulin, a
positive result for any of IgA, IgM, and IgG to blood brain barrier proteins, and a positive result
for any of IgA, IgM, and IgG to neuronal antigens.
Similarly, a diagnosis related to breakdown in blood brain r ity,
neuroinflammation and neuroautoirnmunity, without association with intestinal r or gut
flora dysbiosis are likely where the test s include a negative result for each of IgA, IgM,
and IgG to the bacterial toxin of lipopolysaccharide, and negative results for each of IgA, IgM,
and IgG to occludin and zonulin, a positive result for any of IgA, IgM, and IgG to blood brain
barrier proteins, and a positive result for any of IgA, IgM, and IgG to neuronal antigens.
689IHA3510078NZPR
Regarding specific diseases, analysis of test results contemplated herein can be used to
assist in detecting and diagnosing amyotrophic lateral sclerosis, Parkinsons disease, multiple
sclerosis, Alzheimer’s, or peripheral neuropathy, and major depression. Such conditions are
thought to be likely where the test results include a ve result for any of IgA, IgM, and IgG
to blood brain barrier proteins, and a positive result for any of IgA, IgM, and lgG to al
antigens.
In a first particular aspect the present invention provides a method of testing a sample
from a human, comprising:
measuring a first signal derived from binding of a first antibody fraction of the sample to
a ial lipopolysacccharide; and
measuring a second signal derived from binding of a second antibody fraction of the
sample to one or more human antigen, ed from at least one of (a) one or more lated
antigen and (b) one or more blood brain barrier-related antigen,
wherein the measurement of the first signal is related to the presence of antibody to the
bacterial lipopolysaccharide in the human; and
the measurement of the second signal is related to, for the one or more gut-related
antigen, gut permeability in the human; and
the measurement of the second signal is related to, for the one or more blood brain
barrier-related antigen, blood brain barrier permeability in the human.
In another particular aspect the invention provides a method of diagnosing a disease
associated with leaky gut syndrome in a human, sing:
conducting a method of testing a sample from a human ing to the first particular
aspect of the invention described above;
determining if results from the method indicate gut permeability; and
associating test results ting gut r permeability with the human having a
disease associated with leaky gut syndrome.
In another particular aspect the present invention provides a method of diagnosing a
disease associated with blood brain barrier permeability in a human, comprising:
303741689:HASS 10078NZPR
ting a method of g a sample from a human according to the first particular
aspect of the invention described above;
determining if results from the method indicate blood brain r permeability; and
associating test results indicating blood brain barrier permeability with the human having
a e associated with blood brain-barrier permeability.
In another particular aspect the present invention provides a test plate having as bound
antigens: (l) a ial lipopolysacccharide; and (2) one or more human antigen comprising at
least one of (a) one or more gut—related antigen and (b) one or more blood brain barrier—related
In another particular aspect the present invention provides a method of assisting in
diagnosing a disease or syndrome associated with excessive permeability of an anatomical
barrier, comprising:
conducting a method of testing a sample from a human according to the first particular
aspect of the invention described above;
analyzing the results from the method to determine the presence of antibodies to a
bacterial lipopolysacccharide, and one or more human antigen ed from at least one of (a) a
one or more gut-related antigen and (b) a one or more blood brain barrier-related antigen; and
associating a positive result for antibodies to the one or more lated antigen with a disease
or syndrome associated with excessive permeability of the ical barrier provided by the
intestine of the human and/or a positive result for antibodies to the one or more blood brain
barrier antigen with a disease or syndrome associated with excessive permeability of the
anatomical barrier provided by the blood brain—barrier of the human.
Various objects, features, aspects and advantages of the inventive subject matter of the
present invention will become more apparent from the ing detailed description of
preferred ments, along with the accompanying drawing figures and tables.
303741689IHA5510078NZPR
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l is a prior art diagram showing a tly understood role of LPS in the
induction of leaky gut and leaky brain syndrome.
Fig. 2 is a prior art diagram showing a currently understood role of LPS induction of
inflammation and activation of Thl7 lymphocytes in the pathogenesis of inflammatory and
Neuroimmunological disorders: LPS’ induction of atory response, production of
cytokines, and increase in the number of Th] 7 positive cells in circulation.
Figure 3 is a prior art diagram showing a currently understood etiology of gut to brain
dysfunction -- how loss of mucosal tolerance, if unmanaged, can trigger a cascade that induces
intestinal barrier ction, systemic inflammation, neuroinflammation, neuroinvasion, and
neurodegeneration.
Figure 4 is a m g a proposed scenario of the present invention in which
rs and isms involved in abnormal intestinal permeability and blood brain
permeability can be used for a next generation of testing for intestinal permeability identification
(IPI) and/or blood brain permeability identification (BBPI).
Figure 5 is a diagram showing a proposed role of abnormal intestinal permeability in the
pathogenesis of autoimmune disease according to certain aspects of the present ion.
Figure 6 is a diagram showing the layout of a sample microtiter plate for conducting an
immunoassay, the microtiter plate having 12 different rows with 12 different antigens and
peptides according to certain s of the present invention.
Figure 7 is a diagram showing the layout of a sample microtiter plate according to certain
s of the present invention, in which IgG/IgM/lgA is measured against 12 different antigens
or peptides from intestinal and BBB n and associated tissue antigens (bound antigens and
peptides are transparent).
Figure 8 is a diagram showing the layout of a sample microtiter plate according to
n aspects of the present invention, in which IgG/lgM/lgA is measured with weekly
negative and positive controls for quality control purposes (bound antigens and peptides are
transparent).
Figure 9 is a diagram g a comparison of IgG, IgM and IgA against bacterial
lipopolysaccharide and occludin/zonulin in healthy blood donors and patients with gastric
autoimmunity. The percent elevation of IgG, IgM, IgA and M+IgA against bacterial
lipopolysaccharide in healthy blood donors is shown in the unshaded bars in a Graph A and
patients with gastric munity at two standard-deviations above the mean is shown in the
shaded bars in a Graph A. The percent elevation of IgG, IgM, IgA and IgG+IgM+IgA
against occludin/zonulin in healthy blood donors is shown in the unshaded bars in a Graph B
and patients with gastric autoimmunity at two standard-deviations above the mean is shown
in the shaded bars in a Graph B.
Figure 10 shows IgG, IgM and IgA antibody levels tested t 12 different
antigens representing the environmental factor (LPS), intestinal and BBB proteins and
associated antigens in a first set of three healthy subjects (Samples 1-3), according to n
s of the present invention.
Figure 11 shows IgG, IgM and IgA antibody levels tested against 12 different
antigens representing the environmental factor (LPS), intestinal and BBB proteins and
associated antigens in a second set of three healthy subjects (Samples 4-6), according to
certain aspects of the present invention.
Figure 12 shows IgG, IgM and IgA antibody levels tested against 12 different
antigens representing the nmental factor (LPS), intestinal and BBB proteins and
associated antigens in a third set of three y subjects (Samples 7-9), ing to certain
aspects of the present invention.
Figure 13 shows IgG, IgM and IgA antibody levels tested t 12 different
antigens representing the environmental factor (LPS), intestinal and BBB proteins and
ated antigens in three patients (Samples 10-12) with celiac disease and gut
permeability, according to certain aspects of the present invention.
Figure 14 shows IgG, IgM and IgA antibody levels tested against 12 different
antigens representing the nmental factor (LPS), intestinal and BBB proteins and
associated antigens in three ts (Samples 13-15) with gluten ataxia, according to certain
aspects of the present invention.
Figure 15 shows IgG, IgM and IgA antibody levels tested against 12 different
antigens representing the environmental factor (LPS), intestinal and BBB proteins and
associated antigens in three patients (Samples 16-18) with multiple sclerosis (MS), according
to certain aspects of the present ion.
Figure 16 shows a al interpretation of certain antibodies against LPS, occludin
/zonulin and actomyosin network in blood, according to certain aspects of the present
invention.
Figure 17 shows a clinical interpretation of elevated levels of certain antibodies
against LPS, occludin/zonulin and actomyosin in oral fluid, according to certain aspects of
the present invention.
Figure 18 shows a clinical interpretation of elevated levels of certain antibodies
against LPS, occludin/zonulin, blood brain barrier protein and al antigens in blood,
according to certain aspects of the present invention.
DETAILED DESCRIPTION OF THE GS
An sed uptake of antigens is a prerequisite for disease development. A number
of conditions are known to increase the permeability of the ine and hence increase
antigen uptake. It is likely that the uptake of immunogenic molecules or antigens from the
lumen can result in immunological-mediated activity, both within the intestine in the form of
IgA and IgM, and beyond the intestine with the production of antigen-specific IgA, IgM, IgG
and immune complexes (26, 27).
I. The Effect Of Bacterial Toxins And Inflammatory Cytokines On The
Induction Of Blood-Brain Barrier Disruption And Neuroinflammation
The blood-brain barrier (BBB) maintains the internal nment and ity of the
central nervous system. Structural and functional changes to the BBB may result in
autoimmune diseases, in ular, neuroautoimmune es such as multiple sis
(28).
The BBB separates blood leukocytes, which normally respond to necrotic injury, from
the brain parenchyma where ic cell death might take place in response to
environmental factors such as infections, toxins, excitotoxicity, or trauma (23). The BBB is
composed of two layers. The first layer consists of ascular endothelial cells, which
have abundant tight junctions with structural similarity to that of intestinal epithelial cells (24,
28). The second layer is the glia limitans, which is formed by glial foot processes (29). The
perivascular space between the endothelial cells and astrocytes is populated by macrophages,
which behave like immature dendritic cells (29). Therefore, factors capable of opening the
epithelial TJ r are able to destroy both the BBB and neuronal tissue ). This
includes bacterial endotoxins,
PCT/U82012/022706
proinflammatory cytokines, enzyme and effector cells Th1, Th17, which are essential to central
nervous system inflammation (29, 34-35).
It is firmly established that disruption of the BBB by endotoxins, cytokines, chemokines,
adhesion les, and , and the trafficking of autoreactive T-cells from the systemic
compartment into the central nervous system, play an important role in the development of MS
lesions (36-38). However, when a comparison was made between human Th1 versus Th17
lymphocytes, human Thl7 lymphocyte migrated faster across the BBB than Th1 lymphocytes.
Indeed a significant number of IL-l7- and ILexpressing CD4+CD45RO+ memory
lymphocytes upon their migration across BBB expressed IL—17+ and IL—22’r markers, which
confirmed the ability of Thl7 lymphocytes to cross the BBB in vitro and in vivo (35). The BBB
elial cells expressed IL—17R and IL—22R, which are used by Th17 cytes to
infiltrate the BBB endothelial cells (ECS). This diffusion of cells or antigens, such as bovine
serum albumin (BSA), a macromolecule, across the BBB was enhanced significantly when IL~I7
and IL—22 were added to monolayers of human BBB-ECS. This ed permeability of BBB-
ECS correlated with a decrease in the expression of occludin and n, the two important tight
junction ns (39).
These results strongly suggest that inflammation induced by LPS and other bacterial
toxins g activation of Th17 lymphocyte expression of IL-17 and IL-22 receptors on blood-
brain barrier endothelial cells results in binding of Thl7 to BBB tight ons. This disrupts the
tight junctions, leading to transmigration of Thl7 and autoreactive T cells across the BBB,
release of granzyme-B by the Th17, and interferomgamma by CD4 cells, resulting in al
cell ction, release of neuronal cell antigens and BBB proteins into the circulation (the cells
c0~expressing IL—17, ILv22 and granzyme B through the action of IL-17 and IL-22) play a
significant role in the induction and breach in the BBB and the permeabilization of BBB to
circulating CD4+ lymphocytes and soluble molecules resulting in CNS inflammation (40-44).
The role of T1117 lymphocytes in the pathogenesis of inflammatory and neuroimmunological
disorders is shown in Figure 2. Based on this mechanism of action, bacterial toxin induction of
gut bility and disruption of BBB protein structure can result in antibody production not
only against LPS but also against tight junction proteins and BBB proteins. Therefore, steps for
tackling nflammation according to certain aspects of the t invention begin with
testing for LPS, occludin, claudins, BBB proteins, tightjunction protein, enzymes such as matrix
metalloproteinase and associated receptor antibodies, based on which clinicians can plan the
repair of the gastrointestinal barrier dysfunction, followed by dampening systemic ation
and ending with the restoration of the blood-brain barrier.
PCT/U52012/022706
Expression of IL-17 and IL-22 receptors on blood-brain barrier endothelial cells result in
the g of Thl7 cells to BBB tight junctions. This disrupts the tight junctions, leading to
autoreactive CD4 cells and neurodegeneration. Thl7 cells then transmigrate across the BBB,
setting the stage for the g of neurous by the e of granzyme B. This release of neural
cell antigens results in a vicious cycle ofneuroautoimmunity and neurodegeneration.
Based on information presented here, it is hypothesized that the gut is the starting point
for many neurodegenerative disorders. It begins with imbalanced lora, which releases
copious amounts of lipopolysaccharide (LPS). The abundant LPS endotoxins induces up-
regulation of proinflammatory cytokines TNF-alpha and IL-lbeta, resulting in degradation or
dissociation of "Us and their proteins, including occludin and zonulin. This is followed by
inflammation in the blood stream which travels to the BBB. The ation opens the BBB,
causing mum—infiltration, neuroinflammation, neuroautoimmunity and finally,
neurodegeneration. Figure 3 represents the pathophysiology leading to neurodegeneration; if a
person’s intestinal barrier dysfunction is not addressed, the person could develop
neuroinflammation and possible neurodegeneration over time. Many autoimmune disorders have
le triggers, symptoms, and system dysfunctions. In cases of neuroautoinununity, where
many of the individuals produce high levels of antibodies to the LPS, "Us, and to the BBB
protein, the immune and nervous systems are involved. The common ground for these two
systems is the GI tract, the importance ofwhich has been addressed (43).
Therefore, in certain aspects of the present ion, the detection and measurement of
antibodies t TJ proteins such as occludin, bacterial endotoxins such as LPS, and BBB
proteins is the best way not only to assess GI and intestinal r integrity, but also determine
and/or se the root cause of systemic inflammation, neuroinflammation, neuroinvasion and
egeneration. Also, any s of the intestinal epithelium must be quickly repaired.
ise, this would allow the penetration of dietary proteins, commensal and pathogenic
bacteria into the circulation, driving an inflammatory cascade that would result in complex
autoimmune and neuroimrnune disorders.
11. Measurement of Permeability to Small Sugars versus Large Antigenic Molecules
The current methodology for assessing intestinal permeability uses lactulose and
mannitol. Over the last 40 years, it has been a useful clinical tool. Lactulose absorption suggests
a tear in the gut barrier, and thus, intestinal permeability. Against popular belief, the absorption
of this small molecule ly indicates a minute leak rather than a tear. ose has relatively
low molecular size, and the transfer of this nce h the gut membranes does not reflect
2012/022706
the situation for transfer of food or other proteins, and immune se against them
Furthermore, Lactulose/Mannitol test measures the transfer of small molecules only through
paracellular but not transcellular y.
Therefore, Large Molecule inal bility Identification (LMIPI) should be
assessed using large molecules such as bacterial endotoxins (comparable to the size of food
proteins), which are antigenic and challenge the immune system. Furthermore, in regard to BBB
permeability, although several lines of evidence have revealed that alterations in BBB
permeability are a primary initiating factor in 'MS and experimental autoimmune
encephalomyelitis (BAE) (45-50), there is currently no recognized blood test for the
measurement of BBB permeability. However, in animal models morphological and functional
s in the BBB have been demonstrated by using zonulin/occludin to measure barrier
damage impairment (7, 11, 28).
As shown in Figure 4, the emphasis of the methodology of the present invention is on
large molecules that are nic and which, upon their release from the barriers, have the
ty to challenge the immune system, resulting in the production of specific lgG, IgM and/or
IgA antibodies against them, which are detected in blood, blood serum, and/or saliva samples.
Assessment of intestinal barrier permeability to large antigenic molecules such as
bacterial endotoxins and y proteins is becoming important in the understanding of the
enesis of gastrointestinal and autoimmune diseases. Scientific evidence indicates that
many gastrointestinal and autoimmune disorders are accompanied by an increased translocation
of endotoxins and other ial toxins from aerobic and anaerobic bacteria h the gut wall
(7, 51-55). This increased translocation and the inflammation associated with it may induce
ation of tight junction proteins and a subsequent immune response against tight junction
proteins such as occludin/zonulin and bacterial endotoxins such as LPS. Indeed, rat and human
epithelial cells exposed to bacterial toxins or gliadin secrete a significant amount of zonulin. This
release of zonulin is followed by disengagement of the protein ZO-l from the tight junctional
complex, resulting in intestinal bility through the llular pathway (7, 51). And,
many c conditions are accompanied by increased serum levels of IgA and IgM against
LPS and other antigens of pathogenic bacteria (24, 25). These conditions cause gut inflammation
and l barrier permeability, whereby enlarged spaces between the cells of the gut wall and
dissociation of tight junction proteins can induce losses in the actomyosin network and the
protective barrier. This loss of protective barrier may increase bacterial translocation and thus
enhance the concentration of serum endotoxins, tight junction proteins, and actomyosin.
W0 2012/103324 PCT/U52012/022706
According to certain aspects of the present invention, the increased serum IgA and IgM
against LPS, tight junction protein (occludin/zonulin) and actomyosin indicate the presence of
intestinal barrier bility and the trafficking of macromolecules across the barriers. The
endotoxins of bacteria may be causing the munity through ial toxin acting as
superantigen to T lymphocytes, or by a mechanism called lar mimicry. Many bacteria
have antigenic sites very similar to human tissue antigens, including neuronal tissue. If intestinal
barrier permeability is left unchecked, then the inflammatory cascade of antigens and the
antibodies produced against them will go in turn into various tissues and r first
inflammation and then autoimmunity, ing utoimrnunity. Therefore, if antigenic
intestinal barrier permeability is allowed to run its course, the continued ration can trigger
systemic ation, followed by the induction of antigenic and cellular blood brain barrier
permeability, bringing concomitant additional immune reactions that result in
neuroinflammation, neuroinvasion and neurodegeneration.
Thus, according to certain aspects of the present invention, patients with c
atory and autoimmune conditions should be checked for the existence of increased gut
permeability to large antigenic molecules by measurement of IgA, IgG and/or IgM against
bacterial LPS, tight junction proteins and actomyosin. y, in on to measurement of
IgA, IgG and/or IgM antibodies against LPS and occludin/zonulin, these antibodies should aiso
be measured against BBB proteins, enzymes, associated receptors, and neuronal antigens in
patients with neuroimmune disorders. This multi-step process of TJ degradation by bacterial
toxins and the production of antibodies againstreleased TI proteins, LPS and other ial
antigens, which leads to tissue damage and munity, is illustrated in Figure 5.
ing to certain aspects of the present invention, the ion and measurement of
IgA and IgM in oral fluid and IgG, IgM and IgA in blood against TJ proteins and LPS would be
the best assay for assessment of intestinal barrier function, while the detection and measurement
of LPS, occludin/zonulin and other tight junction proteins, plus BBB proteins and neural cell
antibodies (IgG, IgM and lgA) in blood would be the best method for assessment of
intestinal/BBB permeability and neuroautoimmunity.
Bacterial antigens (LPS) induce degradation of tight junctions and zonulin release,
causing the opening of the tight junctions and the passage of occludin and LPS through the tight
junctions and subsequent migration into the submucosa, where the occludin and LPS are
presented to macrophages and dcndritic cells. Macrophages present these antigens to T and B
cells; this is followed by aberrant immune response, both humoral (IgA, IgM and IgG antibodies
against occludin and LPS) and cell~mediated. This interplay between humoral and cell-mediated
immunity is ultimately responsible for the mune process targeting the intestinal
epithelium and other tissue antigens, leading to the tissue damage typical of mune
diseases.
Following are ary descriptions of assays, and their use and analysis with respect to
some test patients. gh other materials and methods similar or equivalent to those
described herein can be used in the practice or testing of the present invention, the preferred
method and materials now bed in the ary description of assays to further illustrate
the t invention according to certain aspects.
ELISA Assay
A. Materials and Methods —— Plate and Sample Preparation:
Lipopolysaccharides from E. coli 055:85; E. coli K—235, Pseudomonas aeruginosa,
Pseudomonas putida, Salmonella enteritidis, Salmonella typhimurium, Klebsiella pneumonia,
Morganella morganii, Hafnia alvei, Citrobacter koseri, actin, actomyosin, myelin basic protein
and a—B llin were purchased from Sigma-Aldrich, ST. Louis, MO. Glial fibrillary acidic
protein (GFAP) was purchased from Boehringer Mannheim, Indianapolis, IN. Also used were
zonulin peptides 1, 2, 3, intestinal ZOT receptor, myelin basic protein peptide 87-106, cell
junction protein, matrix oproteinmase-B, calcium-binding region of 8100-8 named in this
study, BBB-l MSELEKAMVA LIDVFHQYSG REGDKHKLKK, BBB-2 SELKELINNE
LSHFLEEIKE QEVVDKVMET, BBB-3 LDNDGDGECD FQEFMAFVAM VTTACl-IEFFE
HE, brain ZOT binding protein-l , -2, tectin (MRP—8), and brain ZOT receptor.
All peptides HPLC grade with purity of greater than 90% were synthesized by 132 Biolab
of Carmel, IN. Throughout this application, unless the t dictates the contrary, all ranges
set forth herein should be interpreted as being inclusive of their endpoints, and Open-ended
ranges should be reted to include commercially cal values. Similarly, all lists of
values should be considered as inclusive of intermediate values unless the context indicates the
contrary.
Antigens and peptides were dissolved in methanol at a concentration of 1.0 mg/mL, then
diluted 1:100 in 0.1M carbonate—bicarbonate buffer, pH 9.5, and 50 pl were added to each well
of a polystyrene flat-bottom ELISA plate, as shown in Figure 6.
Plates were incubated overnight at 4°C and then washed three times with 200 pl Tris-
buffered saline (TBS) containing 0.05% Tween 20 (pH 7.4). The non-specific binding of
immunoglobulins was prevented by adding 200 mL of 2% bovine serum albumin (BSA) in TBS,
WO 03324 PCT/U82012/022706
and incubated overnight at 4°C. Plates were washed and after quality central (QC)
were kept at
4°C until used.
The enzyme conjugates included: y Purified Antibody Phosphatase-labeled Goat
anti-Human IgG (Jackson Research, Cat#109008); Affinity Purified Antibody
atase~labeled Goat anti-Human lgA (Jackson lmmunoResearch, Cat#109011); and
y Purified Antibody Phosphatase-labeled Goat anti-Human IgM (Jackson
ImmunoResearch, Cat.#109043).
Other onal reagents and materials included in the method as further described
herein, includes: Phosphate-Buffered Saline Powder (Sigma, Cat#P3813-10PAK), Bovine Serum
Albumin (Biocell, Cat#3203-00), Sodium Azide (Sigma, Cat#S-2002), Tween 20 (Sigma,
Cat#Pl379-1000ML), Glycerol (Sigma, Cat#65516~500ML), Sodium Hydroxide (Sigma,
Cat#S-5881), ium Chloride (Sigma, 66), Diethanolamine (Sigma, Cat#D-8885),
1.0 N Hydrochloric Acid Solution (Sigma, Cat#H3162-1GA), 5mg Substrate Tablets: p~NPP
nitophenyl phosphate) (Sigma, Cat#S-0942), and Distilled water (D. H20).
The microwel] plates were prepared and coated with 12 different gut-brain-associated
antigens or peptides, as shown in Figure 6. Calibrator and positive controls and diluted patient
samples were added to the wells and autoantibodies recognizing different antigens bind during
the first tion. After washing the wells to remove all unbound proteins, d alkaline
phosphatase labeled rabbit anti-human IgG/IgM/IgA unbound conjugate were removed by a
further wash step.
Bound conjugate was visualized with paranitrophenyl phosphate (PNPP) substrate, which
gives a yellow reaction product, the intensity of which is proportional to the concentration of
autoantibody in the sample. Sodium hydroxide was added to each well to stop the reaction. The
intensity of color was read at 405 nm.
Plain red tops or red tiger tops (SST tubes) were used for en collection, although
in certain aspects, other specimen collection tus are conteplated for this assay.
Blood samples were collected using aseptic venipuncture ques and serum was
obtained using standard procedures. In certain aspects, it is preferred that a minimum of 100
microliter of serum for the assay, which therefore corresponds to about one ml or more of blood.
B. Test Assay Procedure
The analytical procedure for IgG, IgM, and/or IgA antibody against LPS, intestinal
and/or BBB proteins is now discussed. In some aspects, all reagents were allowed to reach room
temperature before the test assay was commenced. The test assay procedure es preparing
W0 2012/103324 PCT/U82012/022706
the desired number of coated wells or plates with the desired number and type of antigens and/or
peptides. Once the microtiter wells are prepared, about 100 pl of 1:100 diluted control calibrator
are added to Rows A and B ofthe microtiter plate as shown in Figure 7, which can be done using
a multi-channel pipettor. About 100 pl of 1:100 diluted t’s test , here blood serum,
was added to duplicate wells of rows C and D for the first Clinical Specimen rows E and F for
the second Clinical Specimen and rows G and H for the third Clinical Specimen as shown in
Figure 7.
On a te plate, the periodic (i.e., ) negative and positive controls similar to
clinical specimens in duplicates were conducted, as shown in Figure 8.
The plates were then incubated for about 60 minutes at room temperature. After
incubation, the wells were then emptied and washed four times with PBS using an ELISA
Washer. About 100 pl of optimally d alkaline phosphatase-labeled goat anti-human IgA
was added to the IgA plate or about 100 pl of enzyme-labeled IgG was added to the IgG plate
and anti-IgM was added to the lgM plate at optimal dilution.
The respective plates were then incubated for about 30 to about 60 minutes at room
temperature. About ten minutes before the conjugate-incubation ends, a ate solution was
prepared by mixing about 5 mg of p-nitrophenyl phosphate tablet with about 5 ml of substrate
buffer, which was mixed well until the tablet completely dissolved. Washing four times with
PBS using the ELISA washer was repeated. Then, about 100 pl of ate solution was added
to each well. The plate was then incubated for about 30 minutes at room ature with the
avoidance of any exposure to direct sunlight. The reaction was stopped by adding about 50 pl of
3 N NaOH. The color intensity of the wells were read using a microtiter plate reader at 405 nm
against a blank well, with the absorbence values of calibrators, controls and unknown samples
being recorded.
C. Calculation of Results
Afier the plate was read at 405 nm to obtain the optical density values (OD405), the mean
ODs of the negative controls, the mean ODs of the positive ls and the mean ODs of each
clinical specimen were divided by the mean ODS of calibrators on Rows A and B to obtain each
Index Value (IV).
The Index Value (IV) for each antibody was calculated against the 12 different antigens
by dividing the mean OD of each duplicate sample by the mean OD of the calibrator control
value (for example, divide the mean OD of wells CI and D1 by the mean OD of wells Al and
Bl, the mean OD of wells C2 and D2 by the mean OD of wells A2 and B2, the mean OD of
wells C3 and D3 by the mean OD of wells A3 and B3, etc.).
The results were then compared to the established reference ranges.
Index = Mean OD of ts
Mean OD of calibrators
Index calculation for Zonulin/Occludin
Cal 1 (OD) 0.48
Cal 2 (OD) 0.50
Sample 3 A (OD) 3.4
Sample 3 B (OD) 3.2
Index 6.7
D. Interpretation of Results
i. Pattern of IgG/IgM/IgA Antibody in Patients with Celiac Disease, Gluten
Immune vity and Sensitivity, and Crohn's Disease:
Examples of lgG, IgM, and IgA antibody patterns of 9 healthy subjects (Figures 10-
12) and their comparison with 3 patients with celiac disease and intestinal permeability
(Figure 13), 3 patients with gluten ataxia e 14), and 3 patients with multiple sclerosis
(Figure 15) are shown in Figures 10-15, respectively.
Data interpretation and laboratory differentiation n celiac disease and gluten
immune reactivity/sensitivity/autoimmunity are shown in Figures 16-18.
ii. Pattern of IgG, IgM and IgA Antibody against Intestinal, BBB Proteins and
ated Antigens in Patients with Celiac Disease and Gut Permeability,
Gluten Ataxia, and Patients with MS.
Based on the calculation of indices, the pattern of IgG, IgM and IgA antibodies in the
nine y control subjects es 10-12), 3 patients with celiac disease and gut
permeability (Figure 13), 3 patients with gluten ataxia e 14), and 3 patients with
multiple sclerosis (Figure 15) is shown in Figures 10-15, respectively. Note that in all healthy
subjects, other than LPS and MBP, the dy indices of which may be higher than 1.5 but
not significantly greater than 2.0, the antibody indices against other antigens are lower or
much lower than 1.5 (Figures 10-12).
In patients with celiac disease as confirmed by IgG and IgA against deamidated
α -gliadin 33-mer peptide, tissue transglutaminase (tTg), and gliadin-tTg complex, the pattern
of dy varies from patient to patient.
For example, Sample 10 in Figure 13, these antibodies are significantly elevated
against LPS, zonulin/occludin, intestinal ZOT receptor, cell junction protein, MMP-3, α-B
crystallin, and myelin basic protein, indicating that in addition to enhanced gut permeability
the patient may be suffering from BBB permeability. Sample 11 in Figure 13 shows
significant elevation of antibodies against cell junction protein and inal ZOT receptor,
and moderate elevation against LPS, but not against BBB proteins and neural antigens,
indicating that in addition to celiac disease the patient may be ing from intestinal
permeability, BBB permeability, neuroautoimmunity, and possibly other autoimmunities.
The level of IgG, IgM and IgA antibodies against 12 ent ns representing
gut-to-brain in 3 patients (Samples 13-15) with gluten ataxia is shown in Figure 14. Gluten
ataxia in these patients was confirmed by the presence of IgG and IgA antibodies against
deamidated α-gliadin 33-mer peptide, tTg-2, gliadin-tTg complex, tTg-6 and cerebellar
antigens. In these patients the pattern of antibodies was significantly higher against ZOT-
binding protein, brain ZOT receptor, α-B crystallin, calprotectin, GFAP, and cell junction
protein, confirming barrier damage impairment.
The level of these dies against 12 tested antigens in 3 patients (Samples 16-18)
with MS is summarized in Figure 15. In addition to an al MRI, a diagnosis of MS was
made based on antibody detection against MBP, myelin oligodendrocyte rotein
(MOG), α-B crystallin, proteolipid protein, lymphocyte activation and proinflammatory
cytokine production ( 44). Significant elevation in the level of antibodies was detected t
neuronal antigens, BBB proteins and zonulin/occludin. This is indicative that indeed patients
with MS suffer from BBB ction.
iii. ement of IgG, IgM and IgA antibodies against bacterial
lipopolysaccharide and in/zonulin in patients with gastric
autoimmunity.
inal permeability is significant in gastrointestinal autoimmune disease (4).
Figure 9 shows diagrams that compare the elevation of antibodies t bacterial
endotoxins (lipopolysaccharides) and the structure of the tight junctions (occludin/zonulin) in
y controls and patients with gastric autoimmunity.
The exaggerated entrance of antigenic macromolecules across the gut epithelium can
te tion of, and perpetuate an ongoing increase in, multiple inflammatory
cytokines and systemic chronic inflammation (56). This appears to be a required component
for the trio of factors that lead to eventual autoimmune disease ic vulnerability,
nmental exposure, and intestinal permeability).
According to certain aspects of the present invention, it is hypothesized herein that
elevated antibodies to LPS, occludin/zonulin and the actomyosin network are biomarkers
identifying the breakdown of a healthy intestinal barrier, and that elevated antibodies to LPS,
occludin/zonulin, other cell junction proteins, BBB proteins plus neural antigens (for
example, MBP, α-B crystalline, GFAP, tectin, and brain ZOT protein) not only te
the breakdown of a healthy intestinal barrier, but also a failure in BBB integrity.
Clinical interpretation of elevated level of antibodies against LPS, in/zonulin
and actomyosin in oral fluid according to certain s of the present invention is shown in
Figure 17.
Clinical interpretation of elevated blood level of antibodies against LPS,
in/zonulin, blood brain barrier protein and neural antigens according to certain s
of the present invention is shown in Figure 18.
CASE STUDY EXAMPLES
Two different case reports, the first on a patient with celiac disease and the second
with multiple sclerosis are provided as follows.
A. CASE REPORT #1: Patient With Celiac e And Intestinal Barrier Dysfunction
A 38 year-old woman 5'4" in height weighing 106 lbs with GI disorder including
constipation, diarrhea and pain all over the body, with fibromyalgia-like syndrome and loss
of weight (1-2 lbs per month during the last six months) was examined by an internist. Lab
investigation ed abnormal CBC with hemoglobin of 9.9 g/dl, MCV of 77 fL,
erythrocyte sedimentation rate of 54 mm/1st hr, with low concentration of folate and vitamin
B-12 but high level of liver enzymes and high sensitive C-reactive protein. Detailed
biochemical and immunological es including ANA, rheumatoid factor, T3, T4 and TSH
levels were performed and all tests were within the normal range. After repeated complaints
about GI discomfort, low-grade fever and headache, the patient was referred for GI
evaluation. Colonoscopy and duodenal biopsy were performed and immunohistological
evaluation revealed total s atrophy with Marsh III classification. At this point IgG and
IgA concentrations against gliadin and transglutaminase were checked. Both IgG and IgA
against gliadin and transglutaminase were 3-5 fold higher than the reference range.
In view of the villous atrophy, gliadin and transglutaminase positivity diagnosis of
celiac disease was made. The patient was used with blood, put on anti-inflammatory
medication and started on a gluten-free diet. Three months later, although her overall GI
discomfort had improved and she had gained 4 pounds, her CRP was still elevated, and the
body ache and low-grade fever continued. In view of this and to determine the root cause of
the inflammation and low-grade fever, dies against LPS, zonulin/occludin, and cell
junction proteins were ed. s presented in Figure 13, Sample 10 showed that in
ison to healthy subjects, the patient (Sample 10) had a 3-6 fold increase in IgG, IgM
and IgA antibody levels against LPS, zonulin/occludin and cell junction proteins, indicating
that in addition to celiac disease the patient was suffering from ial translocation, tight
junction damage and leaky gut syndrome to large antigenic molecules.
ingly, in addition to the gluten-free diet, the patient was treated for leaky gut
syndrome with the implementation of a -free diet plus probiotics glutamine,
ylcysteine, EPA/DHA, vitamin D, lactoferrin, xylitol, and boswellic acid. Thirty days
after commencement of this probiotic regimen plus the lectin- and gluten-free diet, the
patient's clinical condition had ed significantly: her fever was down to 37°C and she
had gained an additional 6 lbs. Sixty days later the treatment for leaky gut was reduced to
probiotics only, but the gluten-free diet was continued. One year later all lab tests were
repeated, and the repeat tests for gliadin, transglutaminase, CRO, LPS, and zonulin/occludin
were within the normal range, which was a further indication that management for leaky gut
plus a -free diet was effective in the treatment of this patient who suffered from celiac
disease and leaky gut syndrome.
Discussion: It has been ished in the literature that in addition to villous atrophy
the majority of patients with celiac disease also suffer from leaky gut syndrome. For this
reason, approximately only 50% of patients with celiac disease improve on a gluten-free diet,
with the structure of their villi returning to normal after six months of such treatment. The
mechanism by which leaky gut syndrome is induced in celiac disease is due to the fact that in
some individuals specific gliadin peptides bind to the epithelial cell and cause damage to the
tight junction proteins, causing the release of n/occludin and claudins from the
osa into the blood. In this particular case, some of the patient's symptomatologies
improved on the gluten- free diet, but the gluten-free diet did not ameliorate the matory
cascade induced by the
PCT/U32012/022706
LPS ocation and enhanced gut permeability. However, 30—90 days after entation of
the gluten-free diet plus treatment for repairing the tight junction proteins using natural remedies
(57-61), both clinical matologies and lab test results were back to normal. Thus, it is
ded that patients with celiac disease should be screened for leaky gut for large molecules
that are antigenic, and treated not only for celiac disease but also for repairing the gut barrier.
The inventive subject matter of the present invention provides for this capability.
B. CASE REPORT #2: Patient With le Sclerosis, Gut And Blood-Brain
Barrier Permeability
A 38 year-old man 5’8” in height weighing 182 lbs following a 3-week history of
progressive neck, back and muscle pain with weakness of the limbs was referred to a neurologist.
0n the day prior to referral, he ped difficulty in passing urine with tingling and sensory
disturbance in his trunk and legs to a degree where he was unable to climb stairs. Just over two
years prior to admission, the patient had family problems and had become very sed, for
which he had not sought any help. His l past history was otherwise unremarkable except
for unexplained mild microcytic anemia which had been treated with vitamin B-12 and iron
supplements.
To clarify whether or not the patient may have suffered from a minor stroke or was
suffering from some neurological or autoimmune disorder, a series of immunological profiles
and neurological ations was ted.
Lab investigation revealed normal chemistry and CBC with a hemoglobin result of 10.8
g/dl. The immunological profile including ANA, rheumatoid factor, immune complexes, total
immunoglobulins, cardiolipid antibodies and thyroid function tests were within the normal range.
During further investigation cerebrospinal fluid and blood was collected and examined
for mycobacteria, Borrelia, CMV, EBV, Herpes Type-6, HTLV-I and -2, and syphilis, all of
which were negative. CSF protein was 0.7 g/L, and glucose 2.3 mMol/L.
Neurological examination revealed d corrected visual acuity of 6/48 in the right
eye and 6/36 in the left eye with normal eye movements. The patient had pyramidal weakness in
both legs with mildly-based gait. Pinprick examination demonstrated hemisensory level below
D10 on both sides.
An MRI scan of the brain showed mild white matter abnormalities with mild generalized
atrophy, which has been observed in patients with MS.
30374 1689:HASS 10078NZPR
r, to exclude the possibility of gluten sensitivity, ceIiac disease and leaky gut
syndrome, AGA, tTg antibody, and lactulose/mannitol tests were performed. A celiac screen
revealed both IgG and IgA anti—gliadin antibodies 3-6 fold above the reference range but was
completely negative for IgG and lgA against transglutaminase. In addition, the
lactulose/mannitol test result was highly abnormal. Consequently, the ing additional tests
were med: IgG, IgM and IgA antibody t LPS, zonulin/occludin, intestinal ZOT
receptor, cell junction protein, MMP—3, brain ZOT binding protein, brain ZOT receptor,
calprotectin, GFAP, a-B crystallin, BBB protein, and MBP. Results summarized in Figure 15,
Sample 17 show a significant elevation in antibody levels against MBP and GFAP, confirming
the abnormal MRI findings and a sis of MS. Furthermore, a significant elevation of
antibodies against zonulin/occludin, calprotectin and BBB n indicated involvement of the 5
GI tract with enhanced gut and BBB permeability in this patient (Figure 15). Based on these test
results, the patient was given 1 g intravenous methylprednisolone for five days with some
resultant clinical improvement. At this point the patient was put on B—seron, showing significant
improvement fifteen days later. Furthermore, 200 mg of minocycline IV glutathione, plus
probiotics glutamine, N-acetylcysteine, EP A/DHA, vitamin D, errin, l, and boswellic
acid were given for repairing the damaged BBB and gut barriers. Three months after this
regimen the patient‘s overall health had improved significantly.
It should be apparent to those skilled in the art that many more modifications besides
those already bed are possible without departing from the inventive concepts herein. The
ive subject matter, therefore, is not to be restricted except in the scope of the appended
claims. Moreover, in interpreting both the specification and the , all terms should be
interpreted in the broadest le manner consistent with the context. In particular, the terms
"comprises" and "comprising" should be interpreted as referring to elements, components, or
steps in a non-exclusive manner, indicating that the referenced elements, components, or steps
may be present, or ed, or combined with other elements, ents, or steps that are not
expressly referenced. Where the specification claims refers to at least one of something selected
from the group consisting of A, B, C and N, the text should be interpreted as requiring only
one element from the group, not A plus N, or B plus N, etc.
303741689:HA5510078NZPR
The reference to any prior art in the specification is not, and should not be taken as, an
acknowledgement or any form of suggestion that the prior art forms part of the common general
knowledge in New d.
REFERENCES
1. Walker WA, Sanderson IR. Epithelial barrier function to antigens. Ann NY Acad Sci. 664: 10—
17, 1992.
PCT/U52012/022706
2. Walker WA, Isselbacher KJ. Uptake and transfer of macromolecules by the
intestine. Gaslroenterol. 67: 531-550, 1974.
3. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut.
55: 520, 2006.
4. Fasano A, onohue T. Mechanisms of disease: the role of intestinal r
function in the pathogenesis of gastrointestinal autoimmune diseases. Nat CZz'n Prac
Gastroenterol Hepatol. 2(9): 416-422, 2005.
. Sapone A, Lammers KM, Mazzarella G, et al. ential mucosal IL—17
expression in two n-induced disorders: gluten sensitivity and the autoimmune enteropathy
celiac disease. Int Arch Allergy l. 152: 75-80, 2010.
6. Sapone A, Lammers KM, Casolaro V, et al. Divergence of gut permeability and
mucosal immune gene sion in two glutennassociated conditions: celiac disease and gluten
sensitivity. BMC Med. 9: 23, 2011.
7. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological
door to inflammation, autoimmunity and . Physiol Rev, 91: 151-175, 2011.
8. Shor DB, Barzilai 0, Ram M, et a1. Gluten sensitivity in le sis:
experimental myth or clinical truth? Ann NYAcad Sci, 1 173: 343-349, 2009.
9. Vojdani A, O’Bryan T, Green JA, et a1. Immune response to dietary proteins,
n and cerebellar peptides in en with autism. Nutr Neurosci. 7(3):lSl-l61, 2004.
10. Correale J, Villa A. The blood-brain-barrier in multiple sclerosis: functional roles
and therapeutic targeting. Autoimmunity. 40: 148460, 2007.
11. Morgan L, Shah B, Rivers LE, et al. Inflammation and dephosphorylation of the
tight junction protein occludin in an experimental model of multiple sclerosis. Neurosci. 147:
664-673, 2007.
12. Skardclly M, Armbruster FP, Meixensberger J, et a1. Expression of zonulin, c-kit,
glial fibrillary acidic protein in human gliomas.Transl Oncol. 2: 117-120, 2009.
13. Yacyshyn B, Meddings J, Sadowski D, et a]. Multiple sclerosis patients have
eral blood CD45RO + B cells and increased intestinal permeability. Dig Dis Sci. 41(12):
2493-2498, 1996.
14. Garate I, -Bueno B, Madrigal, JLM et a1. Origin and consequences of brain
toll-like receptor 4 pathway stimulation in an experimental model of depression. JNeuroinflamm.
8:151,1-31, 2011.
. Al-Sadi RM, Ma TY. IL-IB causes an increase in intestinal epithelial tight
junction permeability. J Immunol. 178: 4641-4649, 2007.
PCT/U52012/022706
16. Matysiak-Budnik T, -Collignon A, Megraud F, Heyrnan M. Alterations of
epithelial permeability by Helicobacter and IL-lbeta in vitro: protective effect of rebamipide.
DigDz's Sci, 2001; 46:1558-1566.
17. Turner JR. “Putting the squeeze” on the tight junction: understanding cytoskeleta]
regulation. Semin Cell Dev Biol, 2000; 1 12301-3 08.
18. Ma TY, Hoa NT, Tran DD, Bui V, Pedram A, Mills S, Merryfield M.
Cytochalasin B modulation of Caco-2 tight junction barrier: role of myosin light chain kinase.
Am JPhysz'ol, 2000; 279:6875-G885.
19. Ma TY, Tran D, Hoa N, Nguyen D, Merryfield M, Tamawski A. Mechanism of
extracellular calcium regulation of intestinal lial tight junction permeability: role of
cytoskeletal involvement. Microsc Res Tech, 2000; 51 : 156-168.
. Al—Sadi R, Ye D, ny K, Ma TY. Mechanism of IL-lB~induced increase in
intestinal epithelial tight junction permeability. JImmunol. 2008; 180:5653-5661.
21. Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Schneebrger EB,
Turner JR. Myosin light chain phosphorylation regulates barrier function by remodeling tight
junction structure. J Cell Sci, 2006; 119:2095-2106.
22. Hecht G, Pestic L, Nikcevic G, Koutsouris A, Tripuraneni J, Lorimer Dd, Nowak
G, Guerriero, Jr V, Blson El, Lanerolle PD. sion of the catalytic domain of myosin light
chain kinase increases paracellular bility. Am ol, 1996; 271 :CI 84.
23. Ma TY, Boivin MA, Ye E, Pedrarn A, Said HM. Mechanism of TNF-a
modulation of Caco—2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase
protein expression. Am JPhysiol, 2005; 288264226430.
24. Mae M, Kudera M, Leunis JC. The gut—brain barrier in major depression:
intestinal mucosa] dysfunction with an sed translocation of LPS from gram negative
bacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Euro
Endocrinol Left, 2008; 29:117-124.
. Mac M, Coucke F, Ategis JC. ization of the increased translocation of
endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a ion of
chronic fatigue me. Neuro Endocrine] Left, 2007; 28(6):]01—116.
26. Walker-Smith JA, Ford RP, Phillips AD. The spectrum of gastrointestinal
allergies to food. Ann y, 1984; 53:629-636.
27. Juvonen P, Jakobsson I, Lindberg T. Macromolecular absorption and cow’s milk
allergy. Arch Dis Child, 1990; 65:300-303.
28. Huang XN, FuJ, Wang WZ. The effects of Fasudil on the permeability of the rat
blood-brain barrier and blood-spinal cord barrier following experimental autoimmune
encephalomyelitis. JNeuroimmunol. 239: 61-67, 2011.
29. Lassmann H, ch F, Vass K, Hickey WF. Microglial cells are a component
ofthe perivascular glia limitans. J Neurosci Res, 1991; 28:236-243.
. Schneeberger EB, Lynch RD. The tight junction: a multifunctional complex. Am J
Physiol Cell Physiol, 2004; 2861C1213-C1228.
31. Chen ML, et a]. Disruption of tight ons and induction of ammatory
cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect Immun, 2006;
74:6581—6589.
32. LaPierre LA. The molecular structure of the tight junction. Adv Drug Deliv, 2000;
41:255-264.
33. Wong V, Gumbiner BM. A synthetic peptide corresponding to the extracellular
domain of occludin perturbs the tight junction bility barrier. J Cell Biol, 1997;
l36(2):399-409.
34. Engelhardt B, Rasohoff RM. The ins and outs of the hocyte trafficking to
the CNS: anatomical sites and molecular mechanisms. Trends Immunol, 2005; 26(9):485-495.
. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigenpresenting
cells: different roles for microglia and ytes. Immunol Today, 2000; 21(3):]41-
147.
36. kar RS, Lee YL, Eng LF. Inflammation in traumatic brain injury: role of
cytokines and chemokines. Neurochem Res, 1998; 23(3):329—340.
37. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M,
Biuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote brain barrier
disruption and central nervous system inflammation. Nat Med, 2007; 13: l 173~l 176.
38. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol,
2005; 23:683—747.
39. Biernacki K, Prat A, Blain M, Antel JP. Regulation of Th1 and ThZ lymphocyte
migration by human adult brain endothelial cells. J Neuropathol Exp Neurol, 2001; 60(12):1 127-
1136.
40. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R,
llier A, Reudeihuber TL, Prat A. Angiotensin 11 controls ing function and is
required for blood—brain barrier maintenance: relevance to multiple sis. J Neurosci, 2007;
27(34):9032-9042.
W0 2012/103324 PCT/U82012/022706
41. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H,
Suzumura A. Production and function of IL-17 in microglia. JNeuroimmunol, 2008; 194:54-61.
42. Ganor Y, Teichberg VI, Levite M. TCR activation eliminate glutamate receptor
GLUR3 from the cell surface of normal human T cells via an autocrine/paracrine
me B-
mediated lytic cleavage. JImmunol, 2007; 178:683-692.
43. Vojdani A, Lambert J. A gut feeling for immune dysregulation and
neuroinflamrnation. The Autism File USA, 2009; 31: 56—64.
44. Vojdani A, Vojdani E, Cooper EL. Antibodies to myelin basic protein, myelin
oligodendrocytes peptides, ot-B-crystallin, lymphocyte activation and cytokine production in
patients with le sis. JInlernal Med, 2003; 254: 363-74.
45. Kirk J, Plumb J, Mirakhur M, et a1. Tight junctional abnormality in multiple
sis white matter affects all rs of vessel and is associated with blood-brain barrier
leakage and active demyelination. J Pathol. 2003; 201: 7.
46. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and
disease. Pharmacol Rev, 2005; 57: 173-185.
47. Leech S, Kirk J, Plumb J, et a1. Persistent endothelial abnormalities and blood-
brain barrier leak in primary and secondary progressive multiple sis. Neuropathol Appl
Neurobiol, 2007; 33: 86-98.
48. Persidsky Y, Ramirez SH, Haorah J, et a1. Bllod-brain barrier: structural
components and function under physiologic and pathologic ions. J Neuroimmune
Pharmacol, 2006, 1: 223-236.
49. Reijerkerk A, Kooij G, van der Pol SM, et al. Tissue-type plasminogen activator
is a regulator of monocyte diapedesis through the brain endothelial barrier. J Immunol, 2008;
181: 3567-3574.
50. Wosik K, Cayrol R, t-Devillers A, et al. Angiotension II controls
occluding on and is required for blood-brain barrier maintenance: relevance to multiple
sclerosis. J ci, 2007; 27: 9032—9042.
51. El Asmar, Panigrahi P, d P, et a1. Host-dependent zonulin secretion causes
the impairment of the small intestine barrier function after bacterial exposure. Gastroenterol,
2002; 123: 1607-1615.
52. Balkovetz DF, Katz J. Bacterial invasion of paracellular route: divide and
conquer. Microbes Infect, 2003; 5:613—619.
53. Kuula H et a1. Local systemic responses in matrix metalloproteinase 8-deficient
mice during Porphyromonas gingivalz's—induced periodontitis. Infect Immun, 2009; 77(2):850-859.
PCT/U82012/022706
54. Cywes C., Wessels M.R. Group A Streptococcus tissue invasion by CD44-
ed cell ling. Nature, 2001; 414:648-652.
55. Y Xu, Q Yu. E-cadherin negatively regulated CD44-hyaluronan interaction and
CD44-mediated tumor invasion and branching morphogenesis. J Biol Chem, 2003; 278: 8661-
8668.
56. Garrote J, Gomez—Gonzalez E, Bernardo D, Arranz E, Chirdo F. Celiac disease
pathogenesis: the proinflammatory cytokine network. J Pediatr Gastroenterol Nutr, 2008;
47(Suppl 1).
57. ado Galdeano C, Perdigon G. The probiotic bacillum Lactobacillus casei
induces activation of the mucosal immune system through innate immunity. Clin Vaccine
l, 2006, 13(2):219-226.
58. Wakabayashi H, ra N, Yamauchi K, et al. Modulation of immunity—related
gene expression in small intestine of mice by oral administration of lactoferrin. Clin Vaccine
Immunol, 2006; 13(2):239~245.
59. Han S, Jeong SY, Nam Y], et a]. Xylitol ts inflammatory cytokine
expression induced by lipopolysaccharides from Porphyromonas gingivalis. Clin Dz'ag Lab
Immunol, 2005; 12(11):1285-1291.
60. Chevrier MR, Ryan AB, Lee DY-W, et a1. Boswellia carterz‘t‘ extract in hibits the
cytokines and promotes 'I‘hZ ncs in vitro. CIin Diag Lab Immunol, 2005; 575-580.
61. Syrovets T, Bfichele B, Krauss C, et al. Acetyl~boswellic acids inhibit
1ipopolysaccharide~mcdiated "INF—alpha induction in monocytes by direct interaction with IKB
kinases.J1mmunol, 2005; 174: 498-506.
303741689:HA8510078NZPR
Claims (29)
1. A method of g a sample from a human, sing: ing a first signal derived from binding of a first antibody fraction of the sample to a bacterial lipopolysacccharide; and measuring a second signal derived from binding of a second antibody fraction of the sample to one or more human antigen, selected from at least one of (a) one or more gut-related antigen and (b) one or more blood brain barrier-related antigen, wherein the measurement of the first signal is d to the presence of antibody to the bacterial lipopolysaccharide in the human; and the ement of the second signal is related to, for the one or more gut-related antigen, gut permeability in the human; and the measurement of the second signal is related to, the one or more blood brain r- related antigen, blood brain barrier permeability in the human.
2. The method of claim 1, wherein the gut-related antigen is selected from the list consisting of: (1) an intestinal ural protein; (2) a tight junction protein; (3) a binding receptor to the tight junction protein; and (4) a cell junction protein.
3. The method of claim 1 or claim 2, wherein the blood brain barrier-related antigen is selected from the list consisting of: (1) a blood brain barrier protein; (2) a glial fibrillary acidic protein (GFAP); (3) a matrix metalloproteinase (MMP), (4) a brain ZOT binding protein; (5) a brain ZOT receptor; (6) a calprotectin; and (7) a myelin basic protein.
4. The method of claim 2 or claim 3, wherein the intestinal structural protein comprises actin/actomyosin.
5. The method of any one of claims 2 to 4, wherein the tight junction n is selected from the group consisting of occludin and zonulin. 3037416892HA5510078NZPR
6. The method of any one of claims 2 to 5, wherein the binding receptor to the tight junction protein ses intestinal ZOT receptor.
7. The method of any one of claims 2 to 6, wherein the intestinal ural n comprises matrix metallOproteinase-3 (MMP—3).
8. A method of diagnosing a disease associated with leaky gut syndrome in a human, comprising: conducting a method of any one of claims 1 to 7; ining if results from the method indicate gut bility; and associating test results indicating gut barrier peimeability with the human having a disease associated with leaky gut syndrome.
9. A method of diagnosing a disease associated with blood brain barrier permeability in a human, comprising: conducting a method of any one of claims 1 to 7; determining if results from the method indicate blood brain barrier permeability; and associating test results ting blood brain barrier permeability with the human having a disease associated with blood brain-banier permeability.
10. A test plate having as bound antigens: (1) a bacterial lipopolysacccharide; and (2) one or more human antigen comprising at least one of (a) one or more gut-related antigen and (b) one or more blood brain barrier~related antigen.
11. The test plate of claim 10, wherein the one or more lated antigen is selected from the list consisting of: (1) an intestinal structural protein; (2) a tight junction n; and (3) a binding receptor to the tight junction protein; and (4) a cell junction protein.
12. The test plate of claim 10 or 11, wherein the one or more blood brain barrier—related antigen is selected from the list consisting of: (l) a blood brain barrier protein; (2) a glial 3037416891HASSl0078NZPR fibrillary acidic protein (GFAP); (3) a matrix metalloproteinase (MlVfP), (4) a brain ZOT binding protein; (5) a brain ZOT or; (6) a calprotectin; and (7) a myelin basic protein.
13. A method of ing in diagnosing a e or syndrome associated with excessive permeability of an anatomical barrier, comprising: conducting a method of any one of claims 1 to 7; analyzing the results from the method to determine the presence of antibodies to a bacterial lysacccharide, and one or more human n selected from at least one of (a) a one or more gut-related antigen and (b) a one or more blood brain barrier-related antigen; and associating a positive result for antibodies to the one or more gut-related antigen with a disease or syndrome associated with excessive permeability of the anatomical barrier provided by the intestine of the human and/or a positive result for antibodies to the one or more blood brain barrier antigen with a disease or syndrome associated with excessive permeability of the anatomical barrier provided by the blood brain-barrier of the human.
14. The method of claim 13, wherein the sample is a blood sample.
15. The method of claim 13, wherein the sample is a saliva sample.
16. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis related to gut flora dysbiosis to be likely where the results include: a positive result for any of IgA, IgM, and IgG to the bacterial lipopolysaccharide; negative results for all of IgA, IgM, and IgG to occludin and zonulin; and a negative result for IgG to actomysin.
17. The method of any one of claims 13 to 15, n the method comprises deeming a sis related to breakdown in the anatomical barrier provided by the intestine by bacterial ns, through a paracellular pathway, to be likely where the s include: a ve result for any of IgA, IgM, and IgG to the bacterial lipopolysaccharide; a positive result for any of IgA, IgM, and IgG to occludin or zonulin; and a negative result for IgG to actomysin. 303741689:HASS [0078NZPR
18. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis related to breakdown in the anatomical barrier provided by the ine by other than bacterial antigens, through a paracellular pathway, to be likely where the s include: negative results for all of igA, IgM, and IgG to the bacterial lipopolysaccharide; a positive result for any of IgA, IgM, and IgG to occludin or zonulin; and a negative result for IgA to actomysin.
19. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis related to breakdown in the anatomical barrier provided by the intestine by bacteria, through a transcellular pathway, to be likely where the results include: a positive result for any of IgA, IgM, and IgG to the bacterial lipopolysaccharide; negative results for all of IgA, IgM, and IgG to occludin and zonulin; and a ve result for IgA to actomysin.
20. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis related to own in the integrity of the anatomical barrier provided by the intestine and the anatomical barrier provided by the blood brain barrier induced by the ial lipopolysaccharide to be likely where the results include: a positive result for any of IgA, IgM, and IgG to the bacterial iipopolysaccharide; a positive result for any of IgA, IgM, and IgG to occludin and zonulin; a positive result for any of IgA, IgM, and IgG to blood brain barrier proteins; and a positive result for any of IgA, IgM, and IgG to al ns.
21. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis d to breakdown in the ity of the anatomical barrier provided by the intestine and the ical barrier provided by the blood brain barrier by factors other than the ial lipopolysaccharide to be likely where the test results include: a negative results for all of IgA, IgM, and IgG to the bacterial lipopolysaccharide; a positive result for any of IgA, IgM, and IgG to occludin and zonulin; a positive result for any of IgA, IgM, and IgG to blood brain barrier proteins; and 303741689:HASS I0078NZPR a positive result for any of IgA, IgM, and IgG to al antigens.
22. The method of any one of claims 13 tolS, wherein the method comprises deeming a diagnosis related to gut flora dysbiosis without breakdown in the integrity of the anatomical barrier ed by the ine and with breakdown in the integrity of the anatomical barrier provided by the blood brain barrier to be likely where the test results include: a positive result for any of IgA, IgM, and IgG to the bacterial lipopolysaccharide; negative results for all of IgA, IgM, and IgG to occludin and zonulin; a ve result for any of IgA, IgM, and IgG to blood brain barrier proteins; and a positive result for any of IgA, IgM, and IgG to neuronal antigens.
23. The method of any one of claims 13 to 15, wherein the method comprises deeming diagnosis related to breakdown in the integrity of the anatomical r ed by the blood brain barrier, neuroinflammation and neuroautoimmunity, without association with breakdown in the integrity of the anatomical barrier provided by the intestine or gut flora dysbiosis to be likely where the test results include: ve result for all of IgA, IgM, and IgG to the bacterial lysaccharide; negative results for all of IgA, IgM, and IgG to occludin and zonulin; a positive result for any of IgA, IgM, and IgG to blood brain barrier proteins; and a positive result for any of IgA, IgM, and IgG to neuronal antigens.
24. The method of any one of claims 13 to 15, wherein the method comprises deeming a diagnosis of one of amyotrophic lateral sclerosis, Parkinsons disease, multiple sis, Alzheimer’s, or eral neuropathy, and major depression to be likely where the test results include: a positive result for any of IgA, IgM, and IgG to blood brain barrier proteins; and a positive result for any of IgA, IgM, and IgG to neuronal antigens.
25. A method as claimed in claim 1, substantially as hereinbefore described with particular reference to any one or more of the examples and/or figures. 689:HA5510078NZPR
26. A method as claimed in claim 8, ntially as hereinbefore described with particular reference to any one or more of the examples and/0r figures.
27. A method as claimed in claim 9, substantially as before described with particular reference to any one or more of the examples and/or figures.
28. A test plate as claimed in claim 10, substantially as hereinbefore described with particular reference to any one or more of the examples and/or figures.
29. A method as claimed in claim 13, substantially as hereinbefore described with particular reference to any one or more of the examples and/or figures.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161437244P | 2011-01-28 | 2011-01-28 | |
US61/437,244 | 2011-01-28 | ||
PCT/US2012/022706 WO2012103324A2 (en) | 2011-01-28 | 2012-01-26 | Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614707A NZ614707A (en) | 2015-04-24 |
NZ614707B2 true NZ614707B2 (en) | 2015-07-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9194867B2 (en) | Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto | |
US20200057074A1 (en) | Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease | |
NZ614707B2 (en) | Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto | |
NZ614464B2 (en) | Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease |